(News Bulletin 247) – Aelis Farma announces today the publication of a series of studies around AEF0117, its first drug candidate dedicated to the treatment of disorders related to excessive cannabis consumption (addiction and psychosis).
‘This seminal paper caps more than a decade of research, from the discovery of the natural mechanism the brain uses to antagonize the effects of THC to our proof-of-concept Phase 2a clinical trial with AEF0117,’ said Dr. Piazz, CEO of Aelis Farma.
In the phase 2a trial, AEF0117 caused a statistically significant reduction in the subjective and reinforcing positive effects of cannabis, the laboratory points out.
According to Aelis, the results obtained clearly suggest that AEF0117 could be an effective approach for patients seeking treatment for excessive cannabis use disorders.
Aelis is now conducting a large, placebo-controlled Phase 2b study, in collaboration with Columbia University Irving Medical Center, with 330 participants with cannabis addiction, to evaluate three dose levels of AEF0117 in the treatment of addiction. to cannabis.
The results should be available by mid-2024.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
